Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Once again. Compare the language to the oringinal July 17, 2012 filing.

Pursuant to the TPL Agreement, in the event PDS pays delinquent interest to Alliacense under the Program Agreement, TPL’s distributions from PDS will be reduced by the amount that such delinquent interest was in excess of a specified rate. Further, TPL agreed to guarantee certain payments to Alliacense.

Is this what you want us to compare?

Share
New Message
Please login to post a reply